Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Control. 2024 Jan-Dec;31:10732748241275004. doi: 10.1177/10732748241275004.
To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with regorafenib (hereafter, TACE-regorafenib) or camrelizumab (hereafter, TACE-camrelizumab) for treating hepatocellular carcinoma (HCC) with untreatable progression after TACE and sorafenib therapy.
The medical records of patients with HCC who received TACE-regorafenib or TACE-camrelizumab between September 2018 and December 2023 were retrospectively evaluated. Therapeutic response, overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared between the two groups.
A total of 76 patients were enrolled in this study, with 41 and 35 patients in the TACE-regorafenib and TACE-camrelizumab groups, respectively. The objective response rates in the TACE-regorafenib and TACE-camrelizumab groups were 9.8% and 8.6%, respectively, with no statistically significant difference between the two groups ( = 0.859). Similarly, there was no statistically significant difference in disease control rates between the two groups (61.0% vs 68.6%, = 0.838). The median OS was 11 months in the TACE-regorafenib group and 10 months in the TACE-camrelizumab group, with no significant difference between the two groups ( = 0.348). The TACE-regorafenib group had a median PFS of 7 months, which was significantly longer than that of the TACE-camrelizumab group (4 months, = 0.004). There was no significant difference in the incidence of AEs between the two groups ( = 0.544).
TACE-regorafenib was safe, well-tolerated, and showed promising efficacy in patients with sorafenib-refractory advanced HCC, whereas TACE-camrelizumab demonstrated similar survival benefits.
评估经动脉化疗栓塞（TACE）联合regorafenib（以下简称 TACE-regorafenib）或卡瑞利珠单抗（以下简称 TACE-camrelizumab）治疗 TACE 和索拉非尼治疗后进展不可切除的肝细胞癌（HCC）的疗效和安全性。
回顾性分析 2018 年 9 月至 2023 年 12 月期间接受 TACE-regorafenib 或 TACE-camrelizumab 治疗的 HCC 患者的病历。比较两组患者的治疗反应、总生存期（OS）、无进展生存期（PFS）和不良事件（AEs）。
本研究共纳入 76 例患者，其中 TACE-regorafenib 组和 TACE-camrelizumab 组各 41 例和 35 例。TACE-regorafenib 组和 TACE-camrelizumab 组的客观缓解率分别为 9.8%和 8.6%，两组间无统计学差异（=0.859）。同样，两组疾病控制率也无统计学差异（61.0%比 68.6%，=0.838）。TACE-regorafenib 组的中位 OS 为 11 个月，TACE-camrelizumab 组为 10 个月，两组间无统计学差异（=0.348）。TACE-regorafenib 组的中位 PFS 为 7 个月，明显长于 TACE-camrelizumab 组（4 个月，=0.004）。两组 AEs 的发生率无统计学差异（=0.544）。
TACE-regorafenib 治疗索拉非尼耐药的晚期 HCC 安全、耐受良好，疗效有希望，而 TACE-camrelizumab 则显示出相似的生存获益。
